Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 9-18

  Siddesha, Jalahalli M ^a,b   Valente, Anthony J ^c   Sakamuri, Siva S V P ^b   Yoshida, Tadashi ^b   Gardner, Jason D ^d   Somanna, Naveen ^b   Takahashi, Chiaki ^e   Noda, Makoto ^f   Chandrasekar, Bysani ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KANAZAWA UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse remodeling; Cardiac fibrosis; MMP; Nox4; RECK

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; COLLAGEN; COLLAGEN IA1; COLLAGEN IIIA1; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; RECK PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CARDIAC FIBROBLAST; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; FIBROBLAST; GENE SILENCING; HEART DISEASE; HEART MUSCLE FIBROSIS; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFUSION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION;

MUS;

12-O-TETRADECANOYLPHORBOL-13-ACETATE; 3-(4,5-DIMETHYTHIAZOL-2-YL)-2,5-DIPHENYL TETRAZOLIUM BROMIDE; A DISINTEGRIN AND METALLOPROTEINASE DOMAIN; ACTIVATOR PROTEIN-1; ADAM; ADVERSE REMODELING; ANGIOTENSIN II TYPE 1 RECEPTOR; ANGIOTENSIN II TYPE II RECEPTOR; ANGIOTENSIN RECEPTOR BLOCKERS; AP-1; ARB; AT1; AT2; C-JUN AMINO-TERMINAL KINASE; CARDIAC FIBROBLASTS; CARDIAC FIBROSIS; CARDIOVASCULAR DISEASE; CF; CMV; CVD; CYTOMEGALOVIRUS; DIPHENYLENE IODONIUM; DPI; ECM; EGFP; ELK; ENHANCED GREEN FLUORESCENT PROTEIN; ERK; ETS-LIKE PROTEIN; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED KINASE; GAPDH; GFP; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GLYCOPHOSPHATIDYLINOSITOL; GPI; GREEN FLUORESCENT PROTEIN; JNK; LEFT VENTRICLE; LV; MAPK; MATRIX METALLOPROTEINASE; MEMBRANE TYPE 1-MMP; MITOGEN-ACTIVATED PROTEIN KINASE; MMP; MOI; MT1-MMP; MTT; MULTIPLICITY OF INFECTION; NADPH; NADPH OXIDASE; NF-ΚB; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NOX; NOX4; NUCLEAR FACTOR KAPPA B; REACTIVE OXYGEN SPECIES; RECK; REVERSION-INDUCING-CYSTEINE-RICH PROTEIN WITH KAZAL MOTIFS; ROS; SBP; SHORT HAIRPIN RNA; SHRNA; SIMMP; SMALL INHIBITORY RNA AGAINST MMP; SP1; SPECIFIC PROTEIN 1; SYSTOLIC BLOOD PRESSURE; TACE; TIMP; TISSUE INHIBITOR OF METALLOPROTEINASE; TPA; TPA DNA RESPONSE ELEMENT; TRE; TUMOR NECROSIS FACTOR, ALPHA, CONVERTING ENZYME; UNTRANSLATED REGION; UTR; WILD-TYPE; WT;

ANGIOTENSIN II; ANIMALS; CELL MOVEMENT; COLLAGEN; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GPI-LINKED PROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MYOCARDIUM; NADPH OXIDASE; NF-KAPPA B; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1;

EID: 84885561974     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.09.015     Document Type: Article

References (50)

1. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000, 52(3):415-472.
2. Fan D., Takawale A., Lee J., Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 2012, 5(1):15.
3. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123(2):255-278.
4. Patterson N.L., Iyer R.P., de Castro Bras L.E., Li Y., Andrews T.G., Aune G.J., et al. Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl 2013, 7(7-8):516-527.
5. Chen W., Frangogiannis N.G. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev 2010, 15(5):415-422.
6. Peng J., Gurantz D., Tran V., Cowling R.T., Greenberg B.H. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 2002, 91(12):1119-1126.
7. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 1998, 95(22):13221-13226.
8. Noda M., Oh J., Takahashi R., Kondo S., Kitayama H., Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003, 22(2-3):167-175.
9. Nagini S. RECKing MMP: relevance of reversion-inducing cysteine-rich protein with Kazal motifs as a prognostic marker and therapeutic target for cancer (a review). Anticancer Agents Med Chem 2012, 12(7):718-725.
10. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107(6):789-800.
11. Omura A., Matsuzaki T., Mio K., Ogura T., Yamamoto M., Fujita A., et al. RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem 2009, 284(6):3461-3469.
12. Miki T., Takegami Y., Okawa K., Muraguchi T., Noda M., Takahashi C. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways. J Biol Chem 2007, 282(16):12341-12352.
13. Shanmugam P., Valente A.J., Prabhu S.D., Venkatesan B., Yoshida T., Delafontaine P., et al. Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy. J Mol Cell Cardiol 2011, 50(6):928-938.
14. Valente A.J., Clark R.A., Siddesha J.M., Siebenlist U., Chandrasekar B. CIKS (Act1 or TRAF3IP2) mediates angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy. J Mol Cell Cardiol 2012, 53(1):113-124.
15. Gonzalez-Villalobos R.A., Seth D.M., Satou R., Horton H., Ohashi N., Miyata K., et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol 2008, 295(3):F772-F779.
16. Masson S., Latini R., Bevilacqua M., Vago T., Sessa F., Torri M., et al. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 1998, 37(3):213-217.
17. Roig E., Perez-Villa F., Morales M., Jimenez W., Orus J., Heras M., et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21(1):53-57.
18. Graziani G., Badalamenti S., Del Bo A., Marabini M., Gazzano G., Como G., et al. Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney Int 1993, 44(1):107-114.
19. Simoes e Silva A.C., Diniz J.S., Pereira R.M., Pinheiro S.V., Santos R.A. Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1-7) in end-stage renal disease. Pediatr Res 2006, 60(6):734-739.
20. Valente A.J., Yoshida T., Gardner J.D., Somanna N., Delafontaine P., Chandrasekar B. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal 2012, 24(2):560-568.
21. Venkatachalam K., Venkatesan B., Valente A.J., Melby P.C., Nandish S., Reusch J.E., et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem 2009, 284(21):14414-14427.
22. Valente A.J., Sakamuri S.S., Siddesha J.M., Yoshida T., Gardner J.D., Prabhu R., et al. TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation. Cell Signal 2013, 25(11):2176-2184.
23. Venkatesan B., Valente A.J., Das N.A., Carpenter A.J., Yoshida T., Delafontaine J.L., et al. CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction. Cell Signal 2013, 25(1):359-371.
24. Colston J.T., de la Rosa S.D., Freeman G.L. Impact of brief oxidant stress on primary adult cardiac fibroblasts. Biochem Biophys Res Commun 2004, 316(1):256-262.
25. Schorb W., Conrad K.M., Singer H.A., Dostal D.E., Baker K.M. Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol 1995, 27(5):1151-1160.
26. Olson E.R., Shamhart P.E., Naugle J.E., Meszaros J.G. Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase Cdelta and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 2008, 51(3):704-711.
27. 2 activates Nox4 through PLA2-dependent arachidonic acid production in adult cardiac fibroblasts. FEBS Lett 2005, 579(11):2533-2540.
28. Furman C., Copin C., Kandoussi M., Davidson R., Moreau M., McTaggiart F., et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004, 174(1):93-98.
29. Boixel C., Fontaine V., Rucker-Martin C., Milliez P., Louedec L., Michel J.B., et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003, 42(2):336-344.
30. Lohi J., Lehti K., Valtanen H., Parks W.C., Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000, 242(1-2):75-86.
31. Chang H.C., Liu L.T., Hung W.C. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal 2004, 16(6):675-679.
32. Hsu M.C., Chang H.C., Hung W.C. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 2006, 281(8):4718-4725.
33. Sasahara R.M., Takahashi C., Noda M. Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun 1999, 264(3):668-675.
34. Moore L., Fan D., Basu R., Kandalam V., Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2012, 17(4-5):693-706.
35. Polyakova V., Miyagawa S., Szalay Z., Risteli J., Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008, 12(1):189-208.
36. Qin H., Sun Y., Benveniste E.N. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999, 274(41):29130-29137.
37. Bergman M.R., Cheng S., Honbo N., Piacentini L., Karliner J.S., Lovett D.H. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003, 369(Pt 3):485-496.
38. Lee J.G., Dahi S., Mahimkar R., Tulloch N.L., Alfonso-Jaume M.A., Lovett D.H., et al. Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci U S A 2005, 102(45):16345-16350.
39. Kim H., Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2000, 269(2):401-405.
40. Lan Y.Q., Zhang C., Xiao J.H., Zhuo Y.H., Guo H., Peng W., et al. Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. Mol Vis 2009, 15:1977-1987.
41. Matsusaka H., Ide T., Matsushima S., Ikeuchi M., Kubota T., Sunagawa K., et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006, 47(4):711-717.
42. Lindsey M.L., Escobar G.P., Mukherjee R., Goshorn D.K., Sheats N.J., Bruce J.A., et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006, 113(25):2919-2928.
43. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106(1):55-62.
44. Zile M.R., Baicu C.F., Stroud R.E., Van Laer A., Arroyo J., Mukherjee R., et al. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol 2012, 302(7):H1429-H1437.
45. Takagi S., Simizu S., Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 2009, 69(4):1502-1508.
46. Muraguchi T., Takegami Y., Ohtsuka T., Kitajima S., Chandana E.P., Omura A., et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat Neurosci 2007, 10(7):838-845.
47. Hong K.J., Wu D.C., Cheng K.H., Chen L.T., Hung W.C. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. J Cell Physiol 2013, 10.1002/jcp.24434.
48. Satoh M., Nakamura M., Saitoh H., Satoh H., Maesawa C., Segawa I., et al. Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. Circulation 1999, 99(25):3260-3265.
49. Fedak P.W., Moravec C.S., McCarthy P.M., Altamentova S.M., Wong A.P., Skrtic M., et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006, 113(2):238-245.
50. Odenbach J., Wang X., Cooper S., Chow F.L., Oka T., Lopaschuk G., et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011, 57(1):123-130.